CureVac GmbH win a $2.7 million vaccine prize from the European Commission

LONDON, LONDON, UNITED KINGDOM, June 26, 2014 /EINPresswire.com/ -- CureVac GmbH recently won a $2.7 million vaccine prize from the European Commission for developing prophylactic vaccines that can reach remote areas in the world without the need for cooling. In a statement released last month, Ingmar Hoerr, CEO and co-founder of CureVac, said:

“We are extremely honored that the jury has recognized our results of more than 14 years development of RNActive vaccines as the biggest leap forward in vaccine technology” *Source

Hear more from CureVac when Program Management Oncology Director, Dr Birgit Scheel, presents on cancer immunotherapy at SMi’s 3rd annual Cancer Vaccines conference taking place on 15th and 16th September in London, UK.

With a focus on RNActive®, CureVac will be sharing their insights in a unique presentation entitled: RNActive® for Cancer Immunotherapy. Harnessing the natural power of the immune system to fight the disease and updates on current trials will be just some of the topics addressed by Dr Scheel.

Targeted towards an audience of oncolytic vaccine developers, Cancer Vaccines 2014 will cover sessions on oncolytic vaccines, T cell immune monitoring, cancer immunotherapy, biomarker guided development and future progress.

Key Speakers Include:

• Joseph Melenhorst, Director of the Product Development & Correlative Sciences laboratory, University Of Pennsylvania
• Tom Lillie, Therapeutic Area Head, Oncology, Amgen Ltd
• Alex Karlsson-Parra, CSO, Immunicum AB
• Harpreet Singh, Managing Director, Founder and CSO, Immatics Biotechnologies GmbH
• Christian Ottensmeier, Professor in Experimental Cancer Medicine, University Of Southampton
• Madiha Derouazi, CEO, Amal Therapeutics
• Eric Leire, CEO, DanDrit Biotech


For those who are interested, early bird discounts are currently available with a deadline of 30th June. Recent confirmed booking include: Theravectys, Breast International Group, XEME Biopharma, Boehringer Ingelheim. For further details and to see the full speaker line-up, visit www.cancer-vaccinesevent.com

3rd annual conference on:
Cancer Vaccines
Assess and Quantify Strategies to Enhance Cancer Vaccine Research and Development
15 - 16 September 2014 | Holiday Inn Regents Park, London UK
www.cancer-vaccinesevent.com
Sponsored by Immudex and Scancell

-----end--------

Teri Arri
SMi Group Ltd
+44 (0)20 7827 6162
email us here